Literature DB >> 34688691

FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase.

Nathakan Klinhom-On1, Wunchana Seubwai2, Kanlayanee Sawanyawisuth3, Sumalee Obchoei4, Panupong Mahalapbutr1, Sopit Wongkham5.   

Abstract

AIMS: 5-Fluorouracil (5-FU), a thymidylate synthase (TS) inhibitor, has been used as the first-line chemotherapeutic drug for cholangiocarcinoma (CCA). The side effects and drug resistance have developed the limits of the clinical application of 5-FU in CCA treatment. Upregulation of Forkhead box M1 (FOXM1) and TS were shown to play a significant role in 5-FU resistance. In this study, the effect of Siomycin A (SioA), a FOXM1 inhibitor, on enhancing 5-FU cytotoxicity and reversing 5-FU resistance in CCA cell lines were demonstrated. MAIN
METHODS: Human CCA cell lines, KKU-100 and KKU-213A were used. Cell viability was determined using MTT assay. Expression of FOXM1 and TS proteins were determined using Western blotting. FOXM1 mRNA expression was quantitated using real-time PCR. The combination and dose reduction (DRI) were analyzed according to the Chou and Talalay method. KEY FINDING: Single drug treatment of 5-FU and SioA effectively inhibited CCA cell growth in dose and time dependent fashions. The two CCA cell lines had different responses to 5-FU but exhibited similar sensitivity to SioA. FOXM1 and TS expression were increased in the 5-FU treated cells but were suppressed in the SioA treated cells. A direct binding of SioA, to TS and 5,10-methylene-tetrahydrofolate as an inactive ternary complex was simulated. The combined treatment of 5-FU with SioA showed a synergistic effect with a high DRI and restored 5-FU sensitivity in the 5-FU resistant cells. SIGNIFICANCE: Targeting FOXM1 using SioA in combination with 5-FU might be a strategy to overcome the 5-FU resistance in CCA.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-Florouracil; Bile duct cancer; FOXM1; Isobologram; Siomycin A; Synergistic effect

Mesh:

Substances:

Year:  2021        PMID: 34688691     DOI: 10.1016/j.lfs.2021.120072

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  Urushiol V Suppresses Cell Proliferation and Enhances Antitumor Activity of 5-FU in Human Colon Cancer Cells by Downregulating FoxM1.

Authors:  Ji Hye Jeong; Jae-Ha Ryu
Journal:  Biomol Ther (Seoul)       Date:  2022-05-01       Impact factor: 4.634

2.  CDI Exerts Anti-Tumor Effects by Blocking the FoxM1-DNA Interaction.

Authors:  Woo Dae Jang; Mi Young Lee; Jihye Mun; Gyutae Lim; Kwang-Seok Oh
Journal:  Biomedicines       Date:  2022-07-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.